Therapeutic use for treating of leukemia
US8236811B2 · kind B2 · utility
0Cited by
8References
10Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 16, 2009 |
| Grant date | Aug 7, 2012 |
| Priority date | — |
| Expiry date | Feb 14, 2030 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P43/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The disclosure relates to methods of treating leukaemia, in particular myeloid leukaemia, comprising administering the compound N-[2-(2,1,3-benzothiadiazol-5-ylamino)-6-(2,6-dichlorophenyl)pyrido[2,3-d]pyrimidin-7-yl]-N′-(1,1-dimethylethyl)-urea or a hydrate, a pharmaceutically acceptable salt or a solvate thereof.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.